To amend title XVIII of the Social Security Act to require PDP sponsors of a prescription drug plan under part D of the Medicare program that use a formulary to include certain generic drugs and biosimilar biological products on such formulary, and for other purposes.
Summary
HR8143 mandates Medicare Part D formularies give preferred placement to generic drugs and biosimilars with lower wholesale acquisition costs than brand-name reference products, effective January 1, 2027. This directly benefits pure-play generics manufacturers $VTRS and $TEVA by guaranteeing formulary access and restricting PBM utilization management. The bill is early stage (referred to committee) but has bipartisan sponsorship and clear structural impact on the Part D market.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR8143 mandates preferred formulary placement for generics/biosimilars in Medicare Part D over brand-name drugs, effective January 1, 2027.
- 2.Pure-play generic manufacturers $VTRS and $TEVA are the direct structural beneficiaries, with guaranteed formulary access and restricted PBM utilization management.
- 3.PBMs ($CVS, $CI) and brand drug manufacturers ($PFE) face headwinds from compressed rebate revenue and lost formulary leverage.
- 4.The bill is early stage but has bipartisan sponsorship; passage probability increases if attached to year-end legislation.
Market Implications
Real price data confirms significant divergence in the generics vs brand/PBM trade. TEVA surged 15.34% in the past week alone, closing at $35.34 on April 30 — this is a direct re-rating based on the favorable policy tailwind from this bill and potentially broader generic-friendly sentiment. VTRS is up 11.55% over 30 days to $15.08, approaching resistance at its 52-week high of $16.47. If the bill gains committee traction (hearing scheduled), expect further upside in $VTRS and $TEVA. Conversely, $PFE at $26.67 (down 5% in 30 days) remains under pressure as its portfolio faces Part D exposure — investors should watch for the bill to clear committee as a sell signal for brand-heavy pharma.
Full Analysis
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Mandate requiring Medicare Part D prescription drug plan formularies to place covered generic drugs and at least two biosimilars with a lower wholesale acquisition cost than the reference product in a preferred position, and prohibiting more restrictive utilization management on those generics/biosimilars than on the brand reference drug.
Who must act
All PDP sponsors offering Medicare Part D prescription drug plans that use a formulary (including CVS Health's SilverScript, Cigna's Express Scripts-administered plans, and UnitedHealth's Optum Rx plans).
What happens
Mandated preferential formulary placement and parity in access restrictions increase the volume of generic and biosimilar prescriptions filled under Part D, expanding market share for these drugs at the expense of higher-priced brand-name equivalents, with enforcement beginning January 1, 2027.
Stock impact
Viatris derives approximately 55% of total revenue from generic and biosimilar products. The mandate directly expands Viatris's addressable Part D channel by guaranteeing formulary placement — previously subject to PBM rebate negotiations — for its generic portfolio. The provision favoring drugs with lower wholesale acquisition cost relative to brand reference drugs aligns with Viatris's pricing strategy as a pure-play generics manufacturer.
What the bill does
Requirement that Medicare Part D formularies include each covered generic drug with lower WAC than the reference product in a preferred position, and at least two covered biosimilar biological products with lower WAC than the reference biological product, with a prohibition on restrictive utilization management (prior authorization, step therapy) more stringent than applied to the reference drug.
Who must act
PDP sponsors managing Medicare Part D formularies (including CVS Health, Cigna/Express Scripts, UnitedHealth/Optum Rx, Humana).
What happens
Guaranteed preferred formulary placement for Teva's generic drugs and biosimilars that meet the lower-WAC threshold, eliminating the current system where PBMs can exclude them or place them on non-preferred tiers in favor of higher-rebate brand drugs. The prohibition on differential access restrictions removes a key obstacle to generic uptake in Part D populations.
Stock impact
Teva generates approximately 45% of total revenue from generic medicines and has a growing biosimilar pipeline (including Austedo, Ajovy biosimilars in development). The mandate creates a direct regulatory tailwind for Teva's Part D formulary access, reducing the need to pay PBM rebates for placement. Teva's biosimilar portfolio specifically benefits from the two-biosimilar minimum requirement.
Market Impact Score
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.